| |  Online-Ressource |
|---|
| Verfasst von: | Maremonti, Francesca [VerfasserIn]  |
|---|
| | Tonnus, Wulf [VerfasserIn] |
|---|
| | Gavali, Shubhangi [VerfasserIn] |
|---|
| | Bornstein, Stefan [VerfasserIn] |
|---|
| | Shah, Ajay [VerfasserIn] |
|---|
| | Giacca, Mauro [VerfasserIn] |
|---|
| | Linkermann, Andreas Günter [VerfasserIn] |
|---|
| Titel: | Ferroptosis-based advanced therapies as treatment approaches for metabolic and cardiovascular diseases |
|---|
| Verf.angabe: | Francesca Maremonti, Wulf Tonnus, Shubhangi Gavali, Stefan Bornstein, Ajay Shah, Mauro Giacca and Andreas Linkermann |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | September 2024 |
|---|
| Umfang: | 9 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online veröffentlicht: 27. Juli 2024 ; Gesehen am 28.10.2024 |
|---|
| Titel Quelle: | Enthalten in: Cell death and differentiation |
|---|
| Ort Quelle: | [London] : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 31(2024), 9, Seite 1104-1112 |
|---|
| ISSN Quelle: | 1476-5403 |
|---|
| Abstract: | Ferroptosis has attracted attention throughout the last decade because of its tremendous clinical importance. Here, we review the rapidly growing body of literature on how inhibition of ferroptosis may be harnessed for the treatment of common diseases, and we focus on metabolic and cardiovascular unmet medical needs. We introduce four classes of preclinically established ferroptosis inhibitors (ferrostatins) such as iron chelators, radical trapping agents that function in the cytoplasmic compartment, lipophilic radical trapping antioxidants and ninjurin-1 (NINJ1) specific monoclonal antibodies. In contrast to ferroptosis inducers that cause serious untoward effects such as acute kidney tubular necrosis, the side effect profile of ferrostatins appears to be limited. We also consider ferroptosis as a potential side effect itself when several advanced therapies harnessing small-interfering RNA (siRNA)-based treatment approaches are tested. Importantly, clinical trial design is impeded by the lack of an appropriate biomarker for ferroptosis detection in serum samples or tissue biopsies. However, we discuss favorable clinical scenarios suited for the design of anti-ferroptosis clinical trials to test such first-in-class compounds. We conclude that targeting ferroptosis exhibits outstanding treatment options for metabolic and cardiovascular diseases, but we have only begun to translate this knowledge into clinically relevant applications. |
|---|
| DOI: | doi:10.1038/s41418-024-01350-1 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1038/s41418-024-01350-1 |
|---|
| | kostenfrei: Volltext: https://www.nature.com/articles/s41418-024-01350-1 |
|---|
| | DOI: https://doi.org/10.1038/s41418-024-01350-1 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Cardiovascular diseases |
|---|
| | Metabolic disorders |
|---|
| | Translational research |
|---|
| K10plus-PPN: | 1907014012 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Ferroptosis-based advanced therapies as treatment approaches for metabolic and cardiovascular diseases / Maremonti, Francesca [VerfasserIn]; September 2024 (Online-Ressource)
